Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin
Open accessThe DOI matches its Crossref record; 67 of the 69 references it cites were found in a registry or an index.
Abstract
Heparins have been invaluable therapeutic anticoagulant polysaccharides for over a century, whether used as unfractionated heparin or as low molecular weight heparin (LMWH) derivatives. However, heparin production by extraction from animal tissues presents multiple challenges, including the risk of adulteration, contamination, prion and viral impurities, limited supply, insecure supply chain, and significant batch-to-batch variability. The use of animal-derived heparin also raises ethical and religious concerns, as well as carries the risk of transmitting zoonotic diseases. Chemoenzymatic synthesis of animal-free heparin products would offer several advantages, including reliable and scalable production processes, improved purity and consistency, and the ability to produce heparin polysaccharides with molecular weight, structural, and functional properties equivalent to those of the United States Pharmacopeia (USP) heparin, currently only sourced from porcine intestinal mucosa. We report a scalable process for the production of bioengineered heparin that is biologically and compositionally similar to USP heparin. This process relies on enzymes from the heparin biosynthetic pathway, immobilized on an inert support and requires a tailored N -sulfoheparosan with N -sulfo levels similar to those of porcine heparins. We also report the conversion of our bioengineered heparin into a LMWH that is biologically and compositionally similar to USP enoxaparin. Ultimately, we demonstrate major advances to a process to provide a potential clinical and sustainable alternative to porcine-derived heparin products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the endothelial cell cultures in our model, commonly used supplements like heparin, which is animal derived, can be replaced with biochemically synthesized alternatives (Douaisi et al., 2024).”
From Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip (2024) · cites this paper as Douaisi et al., 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Collins, R., Scrimgeour, A., Yusuf, S., & Peto, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805053181805 · Cited by 1,314
Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis
Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., et al. (1999) · Nature Medicine · doi:10.1038/10518 · Cited by 803
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events
Guerrini, M., Beccati, D., Shriver, Z., Naggi, A., Viswanathan, K., Bisio, A., Capila, I., Lansing, J. C., Guglieri, S., Fraser, B., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1407 · Cited by 628
Self-citationContaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System
Kishimoto, T. K., Viswanathan, K., Ganguly, T., Elankumaran, S., Smith, S., Pelzer, K., Lansing, J. C., Sriranganathan, N., Zhao, G., Galcheva-Gargova, Z., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803200 · Cited by 621
Prandoni, P., Carta, M., Cogo, A., Ruol, A., Vigo, M., Casara, D., Lensing, A. W. A., Büller, H. R., & ten Cate, J. W. (1992) · The Lancet · doi:10.1016/0140-6736(92)91054-c · Cited by 583
THE THROMBOPLASTIC ACTION OF CEPHALIN
McLean, J. (1916) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1916.41.2.250 · Cited by 530
Conformation and dynamics of heparin and heparan sulfate
Mulloy, B., & Forster, M. J. (2000) · Glycobiology · doi:10.1093/glycob/10.11.1147 · Cited by 315
Protein Design: From the Aspect of Water Solubility and Stability
Qing, R., Hao, S., Smorodina, E., Jin, D., Zalevsky, A., & Zhang, S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00757 · Cited by 312
Linhardt, R. J. (2016) · Frontiers in Bioscience · doi:10.2741/4462 · Cited by 232
Self-citationA proteoglycan form of heparin and its degradation to single-chain molecules.
Robinson, H. C., Horner, A. A., Höök, M., Ogren, S., & Lindahl, U. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37973-5 · Cited by 211
Research works printed but not linked: 1
- 10.1160/th11-07-0518 · doi:10.1160/th11-07-0518
Cited by
Fetal bovine serum: how to leave it behind in the pursuit of more reliable science
Weber, T., Malakpour‐Permlid, A., Chary, A., D’Alessandro, V., Haut, L., Seufert, S., Wenzel, E. V., Hickman, J. J., Bieback, K., Wiest, J., et al. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1612903 · Cited by 53
Surface biofunctionalised porous materials: advances, challenges, and future prospects
Zhang, A., Wong, K. U., Xia, Y., Bilek, M., Yeo, G. C., & Akhavan, B. (2025) · Progress in Materials Science · doi:10.1016/j.pmatsci.2025.101518 · Cited by 31
Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy
Sultana, R., & Kamihira, M. (2024) · Pharmaceuticals · doi:10.3390/ph17101362 · Cited by 20
Quality control, safety assessment and preparation approaches of low molecular weight heparin
Yu, Y., Song, Y., Zhao, Y., Wang, N., Wei, B., Linhardt, R. J., Dordick, J. S., Zhang, F., & Wang, H. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122216 · Cited by 20
Self-citationBioengineered heparin: Advances in production technology
Sultana, R., & Kamihira, M. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108456 · Cited by 20
Metadata
- Authors
- Douaisi, M., Paskaleva, E. E., Fu, L., Grover, N., McManaman, C. L., Varghese, S., Brodfuehrer, P. R., Gibson, J. M., de Joode, I., Xia, K., Brier, M. I., Simmons, T. J., Datta, P., Zhang, F., Onishi, A., Hirakane, M., Mori, D., Linhardt, R. J., & Dordick, J. S.
- Affiliations
- Rensselaer Polytechnic Institute (US)
- Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180
- Corresponding author
- Linhardt, Robert J.
- Dordick, Jonathan S.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2024-03-18
- Volume
- 121
- Issue
- 14
- Pages
- e2315586121-e2315586121
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC10998570
- OpenAlex
- W4392931669
- Cited by
- 31
- References
- 69
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 5
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Heparin Applied Research Center (NA)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Agricultural and Biological Sciences › Food Science › Polysaccharides Composition and Applications
- Keywords
- heparin, low molecular weight heparin, enoxaparin, chemoenzymatic synthesis, immobilized enzymes
- MeSH terms
- Animals, Anticoagulants, Drug Contamination, Heparin, Heparin, Low-Molecular-Weight, Molecular Weight, Swine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin. https://app.cochat.ai/papers/10.1073/pnas.2315586121
- The paper
- Douaisi, M., Paskaleva, E. E., Fu, L., Grover, N., McManaman, C. L., Varghese, S., Brodfuehrer, P. R., Gibson, J. M., de Joode, I., Xia, K., Brier, M. I., Simmons, T. J., Datta, P., Zhang, F., Onishi, A., Hirakane, M., Mori, D., Linhardt, R. J., & Dordick, J. S. (2024). Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2315586121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.